Citadel Advisors
KRYS icon

Citadel Advisors’s Krystal Biotech KRYS Stock Holding History

Citadel Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.71M Buy
10,500
+6,400
+156% +$1.7M ﹤0.01% 5467
2025
Q4 		$1.01M Sell
4,100
-26,000
-86% -$5.47M ﹤0.01% 7374
2025
Q3 		$5.31M Buy
30,100
+11,600
+63% +$1.74M ﹤0.01% 4252
2025
Q2 		$2.54M Buy
18,500
+15,600
+538% +$2.29M ﹤0.01% 5267
2025
Q1 		$523K Sell
2,900
-10,000
-78% -$1.68M ﹤0.01% 8375
2024
Q4 		$2.02M Buy
12,900
+5,100
+65% +$905K ﹤0.01% 5597
2024
Q3 		$1.42M Sell
7,800
-600
-7% -$116K ﹤0.01% 6169
2024
Q2 		$1.54M Sell
8,400
-25,700
-75% -$4.31M ﹤0.01% 5794
2024
Q1 		$6.07M Buy
34,100
+17,400
+104% +$2.42M ﹤0.01% 3643
2023
Q4 		$2.07M Buy
16,700
+1,000
+6% +$111K ﹤0.01% 5290
2023
Q3 		$1.82M Sell
15,700
-13,800
-47% -$1.68M ﹤0.01% 5390
2023
Q2 		$3.46M Buy
29,500
+11,600
+65% +$1.18M ﹤0.01% 4217
2023
Q1 		$1.43M Sell
17,900
-8,000
-31% -$629K ﹤0.01% 6008
2022
Q4 		$2.05M Buy
25,900
+12,000
+86% +$891K ﹤0.01% 5436
2022
Q3 		$969K Sell
13,900
-3,600
-21% -$260K ﹤0.01% 7059
2022
Q2 		$1.15M Sell
17,500
-800
-4% -$49.8K ﹤0.01% 6715
2022
Q1 		$1.22M Sell
18,300
-59,300
-76% -$3.7M ﹤0.01% 7254
2021
Q4 		$5.43M Buy
77,600
+67,800
+692% +$3.95M ﹤0.01% 4149
2021
Q3 		$512K Sell
9,800
-6,700
-41% -$397K ﹤0.01% 9806
2021
Q2 		$1.12M Buy
16,500
+10,500
+175% +$733K ﹤0.01% 8067
2021
Q1 		$462K Buy
+6,000
New +$436K ﹤0.01% 9844

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's KRYS Position: Q1 2026 in Review

Citadel Advisors reduced its Krystal Biotech (KRYS) stake by 99% in Q1 2026, selling an estimated $102M and leaving 2,726 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #8483.

Citadel Advisors first reported a position in KRYS in Q4 2018 and has held it in 26 quarters since. The position peaked at $112M in Q3 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Citadel Advisors held 2,726 shares of Krystal Biotech worth $704K as of Q1 2026.
  • Citadel Advisors sold 383,779 Krystal Biotech shares in Q1 2026, an estimated $102M.
  • Krystal Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8483 holding.
  • Citadel Advisors first reported a position in Krystal Biotech in Q4 2018 and has held it in 26 quarters since.
  • Citadel Advisors's Krystal Biotech position peaked at $112M in Q3 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.